What is the 13F Pro Quality Score for CYCN?

13F Pro ranks Cyclerion Therapeutics, Inc. (CYCN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CYCN's current score at https://13fpro.ai/company/CYCN (free sign-up required for the full ranking).

Which hedge funds own the most CYCN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CYCN include Kalehua Capital Management, FMR, BALYASNY ASSET MANAGEMENT L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CYCN as soon as new 13F filings post.

Where does 13F Pro source CYCN data?

All Cyclerion Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cyclerion Therapeutics, Inc. files with the SEC under CIK 1755237. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CYCN in?

Cyclerion Therapeutics, Inc. (CYCN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CYCN research updated on 13F Pro?

CYCN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cyclerion Therapeutics, Inc.(CYCN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1755237 CYCN stock profile & AI dashboard →

13F Pro Quality Score

19.3/100

Rank #2,795 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CYCN Scores 19/100

exact factor attribution · 2026-09-11

CYCN's composite is driven by institutional flow, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+2.5 pts

100th pct

Earnings quality

-1.1 pts

39th pct

Shareholder dilution

-1.9 pts

13th pct

Earnings growth

-2.2 pts

5th pct

Revenue growth

-4.0 pts

30th pct

Capital efficiency

-4.5 pts

5th pct

Profitability

-6.2 pts

9th pct

Free cash flow

-6.2 pts

8th pct

Scale

-7.0 pts

3th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CYCN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Cyclerion Therapeutics, Inc. (CYCN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CYCN at 19.3/100 on a 32-signal composite quality model, placing it at rank #2,795 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Cyclerion Therapeutics, Inc. reports net income of $-1.8M, free cash flow of $-1.4M. Top institutional holders of CYCN by reported 13-F value include Kalehua Capital Management, FMR, BALYASNY ASSET MANAGEMENT L.P., based on the most recent SEC filings. CYCN trades on the Nasdaq exchange and files with the SEC under CIK 1755237. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYCN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cyclerion Therapeutics, Inc. directly from SEC EDGAR. Cyclerion Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 23 since 2021, currently 19.3 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.

✦

Fun facts about Cyclerion Therapeutics, Inc.

Quirks, history, and lore behind CYCN — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · focused on serious cardiopulmonary diseases · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
A true pre-revenue biotech — no approved products yet — with a small-cap market footprint and a balance sheet kept alive by cash runway rather than sales.
3
The History
Spun out of Ironwood Pharmaceuticals in 2019, taking with it a focused pipeline aimed at a signaling pathway that Ironwood had quietly been developing for years.
4
The Secret
Its entire scientific thesis lives inside the soluble guanylate cyclase (sGC) pathway — a molecular lever that controls blood vessel relaxation and could unlock treatments for heart failure and pulmonary hypertension.
5
The Lore
Its lead program, praliciguat, explored sGC stimulation in heart failure with preserved ejection fraction — a notoriously difficult indication where many larger companies have failed.
6
The Giveaway
The name is practically a cheat code: "cycler" nods to the cyclic GMP biology at its core, and the ticker CYCN makes the wordplay impossible to miss.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$-1.8M

Free Cash Flow

Q2 2026

$-1.4M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+3.7% YoY

$2.1MFY 2025

FY22 $297.0KFY23 $0.00FY24 $2.0MFY25 $2.1M

Net Income

-15.4% YoY

$-3.5MFY 2025

FY22 $44.1MFY23 $-5.3MFY24 $-3.1MFY25 $-3.5M

Operating Income

-37.1% YoY

$-5.0MFY 2025

FY22 $-18.5MFY23 $-13.0MFY24 $-3.6MFY25 $-5.0M

EPS (Diluted)

+8.3% YoY

$-1.11FY 2025

FY22 $-20.28FY23 $-2.25FY24 $-1.21FY25 $-1.11

Total Assets

+4.3% YoY

$10.0MFY 2025

FY22 $18.1MFY23 $13.4MFY24 $9.6MFY25 $10.0M

Total Debt

—FY 2025

FY22 $3.5MFY23 —FY24 —FY25 —

Op. Cash Flow

+23.5% YoY

$-3.3MFY 2025

FY22 $-40.6MFY23 $-21.2MFY24 $-4.3MFY25 $-3.3M

Free Cash Flow

—FY 2025

FY22 $-40.6MFY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.1M +3.7%	$2.0M	$0.00 -100.0%	$297.0K -92.5%	$3.9M +71.7%	$2.3M
Net Income	$-3.5M -15.4%	$-3.1M +41.9%	$-5.3M -111.9%	$44.1M +185.4%	$-51.6M +33.6%	$-77.8M
Operating Income	$-5.0M -37.1%	$-3.6M +72.0%	$-13.0M +30.1%	$-18.5M +66.4%	$-55.2M +32.1%	$-81.3M
EPS (Diluted)	$-1.11 +8.3%	$-1.21 +46.2%	$-2.25 +88.9%	$-20.28 -1436.4%	$-1.32	—
Total Assets	$10.0M +4.3%	$9.6M -28.4%	$13.4M -26.0%	$18.1M -69.5%	$59.3M -48.6%	$115.4M
Total Debt	—	—	—	$3.5M +0.0%	$3.5M +0.0%	$3.5M
Operating Cash Flow	$-3.3M +23.5%	$-4.3M +79.6%	$-21.2M +47.7%	$-40.6M -11.2%	$-36.5M +49.6%	$-72.5M
Free Cash Flow	—	—	—	$-40.6M -11.2%	$-36.5M +50.7%	$-74.0M

Get alerted when CYCN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cyclerion Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CYCN

Kalehua Capital Management LLC
$5.6M1,651,350 sh
FMR LLC
$2.2M649,547 sh
BALYASNY ASSET MANAGEMENT L.P.
$1.1M317,511 sh
ADAR1 Capital Management, LLC
$1.0M298,757 sh
BRAIDWELL LP
$531.9K156,890 sh
CITADEL ADVISORS LLC
$202.7K59,795 sh
GEODE CAPITAL MANAGEMENT, LLC
$155.5K45,850 sh
VANGUARD CAPITAL MANAGEMENT LLC
$104.8K30,915 sh
Rangeley Capital, LLC
$82.4K24,310 sh
HRT FINANCIAL LP
$74.0K22,054 sh

Fund	Value	Shares
Kalehua Capital Management LLC	$5.6M	1,651,350
FMR LLC	$2.2M	649,547
BALYASNY ASSET MANAGEMENT L.P.	$1.1M	317,511
ADAR1 Capital Management, LLC	$1.0M	298,757
BRAIDWELL LP	$531.9K	156,890
CITADEL ADVISORS LLC	$202.7K	59,795
GEODE CAPITAL MANAGEMENT, LLC	$155.5K	45,850
VANGUARD CAPITAL MANAGEMENT LLC	$104.8K	30,915
Rangeley Capital, LLC	$82.4K	24,310
HRT FINANCIAL LP	$74.0K	22,054

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CYCN on your watchlist

Track score changes the day Cyclerion Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CYCN a good stock to buy?

13F Pro's AI-powered analysis of Cyclerion Therapeutics, Inc. (CYCN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CYCN are available on the CYCN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CYCN is classified as a small company.

Which hedge funds own CYCN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CYCN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cyclerion Therapeutics, Inc.'s investment landscape.